Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers

Frontiers in Immunology

Ali Ramazani¹  Serge Muyldermans²  Roghaye Arezumand³  Javad Ranjbari⁴  Abbas Alibakhshi⁴ 

[1] Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences, Zanjan, Iran;Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium;Department of Biotechnology and Molecular Science, School of Medicine, North Khorasan University of Medical Sciences, Bojnourd, Iran;Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran;

关键词: angiogenesis;    nanobody;    monoclonal antibody;    cancer therapy;    vascular endothelial growth factor family;   

DOI  :  10.3389/fimmu.2017.01746

来源: DOAJ

【 摘 要 】

Solid cancers are dependent on angiogenesis for sustenance. The FDA approval of Bevacizumab in 2004 inspired many scientists to develop more inhibitors of angiogenesis. Although several monoclonal antibodies (mAbs) are being administered to successfully combat various pathologies, the complexity and large size of mAbs seem to narrow the therapeutic applications. To improve the performance of cancer therapeutics, including those blocking tumor angiogenesis, attractive strategies such as miniaturization of the antibodies have been introduced. Nanobodies (Nbs), small single-domain antigen-binding antibody fragments, are becoming promising therapeutic and diagnostic proteins in oncology due to their favorable unique structural and functional properties. This review focuses on the potential and state of the art of Nbs to inhibit the angiogenic process for therapy and the use of labeled Nbs for non-invasive in vivo imaging of the tumors.

【 授权许可】

Unknown